



Co-Amoxiclav Clavospey

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory.

500 mg/125 mg Film-Coated Tablet
875 mg/125 mg Film-coated Tablets
ANTIBACTERIAL

DESCRIPTION

Amoxicillin and potassium clavulanate is an oral antibacterial combination consisting of the semisynthetic antibiotic amoxicillin and the β -lactamase inhibitor, potassium clavulanate (the potassium salt of clavulanic acid).

Amoxicillin is an analog of ampicillin, derived from the basic penicillin nucleus, 6-aminopenicillanic acid. The amoxicillin molecular formula is C₁₆H₁₉N₃O₅S₃H₂O and the molecular weight is 419.46. Chemically, amoxicillin is (2S,5R,6R)- 6-[[{(2R)-2-amino- 2-(4-hydroxyphenyl)- acetyl]amino)- 3,3-dimethyl- 7-oxo- 4-thia- 1-azabicyclo[3.2.0]heptane- 24-carboxylic acid trihydrate.

Clavulanic acid is produced by the fermentation of *Streptomyces clavuligerus*. It is a β -lactam compound structurally related to the penicillins and possesses the ability to inactivate a wide variety of β -lactamases by blocking the active sites of these enzymes. The potassium clavulanate molecular formula is C₈H₈KNO₅ and the molecular weight is 237.25. Chemically potassium clavulanate is potassium (Z)-(2R, 5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]-heptane-2-carboxylate.

COMPOSITION

Clavospey

Each film-coated tablet contains:
Amoxicillin500 mg
(as Amoxicillin Trihydrate BP)
Clavulanic Acid125 mg
(as Potassium Clavulanate)

Clavospey

Each film-coated tablet contains:
Amoxicillin Trihydrate USP
equivalent to Amoxicillin 875 mg
Potassium Clavulanate
equivalent to Clavulanic Acid125 mg

CLINICAL PHARMACOLOGY

Mechanism of action

Amoxicillin is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative microorganisms.

Amoxicillin is, however, susceptible to degradation by β -lactamases. Clavulanic acid is a β -lactam compound, structurally related to the penicillins, which

possesses the ability to inactivate a wide range of β -lactamase

enzymes commonly found in microorganisms resistant to penicillins and cephalosporins. In particular, it has good activity against the clinically important plasmid-mediated β -lactamases frequently responsible for transferred drug resistance.

The formulation of amoxicillin and clavulanic acid protects amoxicillin from degradation by β -lactamase enzymes and effectively extends the antibiotic spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin and other β -lactam antibiotics. Thus, the combination possesses the properties of a broad-spectrum antibiotic and a β -lactamase inhibitor.

Microbiology

Amoxicillin/clavulanic acid has been shown to be active against most strains of the following microorganisms.

Gram positive aerobes:

Staphylococcus aureus (β -lactamase and non- β -lactamase producing) *Staphylococci*, which are resistant to methicillin/oxacillin must be considered resistant to amoxicillin/clavulanic acid.

Gram negative aerobes:

Enterobacter species (Although most strains of *Enterobacter species* are resistant in vitro, clinical efficacy has been demonstrated with amoxicillin and clavulanate the combination in urinary tract infections caused by these organisms.)

Escherichia coli (β -lactamase and non- β -lactamase producing).

Haemophilus influenzae (β -lactamase and non- β -lactamase producing).

Klebsiella species (All known strains are β -lactamase producing).

Moraxella catarrhalis (β -lactamase and non- β -lactamase producing).

Amoxicillin and clavulanic acid also demonstrates in vitro activity against the following microorganisms but the clinical significance is unknown.

Gram positive aerobes:

- *Staphylococcus epidermidis* (β -lactamase and non- β -lactamase producing)
- *Staphylococcus saprophyticus* (β -lactamase and non- β -lactamase producing)
- *Streptococcus pneumoniae*
- *Streptococcus pyogenes*
- Viridans group *Streptococcus*
- *Enterococcus faecalis*.

Gram negative aerobes:

- *Neisseria gonorrhoeae* (β -lactamase and non- β -lactamase producing).
- *Proteus mirabilis* (β -lactamase and non- β -lactamase producing).
- *Eikenella corrodens* (β -lactamase and non- β -lactamase producing).

Anaerobic bacteria:

- *Bacteroides species*, including *Bacteroides fragilis* (β -lactamase and non- β -lactamase producing).
- *Fusobacterium species* (β -lactamase and non- β -

lactamase producing).

- *Peptostreptococcus species*.

Pharmacokinetics

Amoxicillin and potassium clavulanate are well absorbed from the gastrointestinal tract after oral administration of amoxicillin and potassium clavulanate tablet. Dosing in the fasted or fed state has minimal effect on the pharmacokinetics of amoxicillin. While amoxicillin and potassium clavulanate tablet can be given without regard to meals, absorption of potassium clavulanate when taken with food is greater relative to the fasted state.

Amoxicillin diffuses readily into most body tissues and fluids with the exception of the brain and spinal fluid. The results of experiments involving the administration of clavulanic acid to animals suggest that this compound, like amoxicillin, is well distributed in body tissues.

Neither component in amoxicillin and potassium clavulanate tablet is highly protein-bound; clavulanic acid has been found to be approximately 25% bound to human serum and amoxicillin approximately 18% bound.

Amoxicillin is metabolized to a limited extent to penicilloic acid. The metabolic fate of potassium clavulanate has not been fully elucidated. However, the drug appears to be extensively metabolized.

Approximately 50% to 70% of amoxicillin and approximately 25% to 40% of clavulanic acid are excreted unchanged in the urine during the first 6 hours after administration of single amoxicillin and potassium clavulanate 375 or 625 mg tablet. The half-life of amoxicillin after the oral administration of amoxicillin and potassium clavulanate is 1.3 hours and that of clavulanic acid is 1.0 hour.

INDICATIONS

For the treatment of urinary tract infection due to susceptible organisms; otitis media or sinusitis due to resistant microorganisms, e.g., *H. Influenzae*, *S. Pneumoniae*, *M. Catarrhalis*; lower respiratory tract and skin infections due to susceptible organisms; polymicrobial infections with mixed aerobic and anaerobic such as diabetic foot, gynecologic infections, intraabdominal infections.

CONTRAINDICATIONS

Amoxicillin and potassium clavulanate combination is contraindicated in patients with a history of allergic reactions to any penicillin and other ingredients of the formulation. It is also contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin and potassium clavulanate combination.

WARNINGS

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy. These reactions are more likely to occur in individuals with a history of penicillin

hypersensitivity and/or a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe reactions when treated with cephalosporins. Before initiating therapy with amoxicillin and potassium clavulanate combination, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins or other allergens. If an allergic reaction occurs, amoxicillin and potassium clavulanate combination should be discontinued and the appropriate therapy instituted. Serious anaphylactic reactions require immediate emergency treatment with epinephrine, oxygen, intravenous steroids and airway management, including intubation, should also be administered as indicated.

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including amoxicillin and potassium clavulanate combination, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*. CDAD must be considered in all patients who present with diarrhea following antibiotic use. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of *C. difficile*, and surgical evaluation should be instituted as clinically indicated.

Amoxicillin and potassium clavulanate combination should be used with caution in patients with evidence of hepatic dysfunction. Hepatic toxicity associated with the use of amoxicillin and potassium clavulanate combination is usually reversible. On rare occasions, deaths have been reported. These have generally been cases associated with serious underlying diseases or concomitant medications.

Erythematous rashes have been associated with glandular fever in patients receiving amoxicillin.

PRECAUTIONS

General

While amoxicillin and potassium clavulanate combination possesses the characteristic low toxicity of the penicillin group of antibiotics, periodic assessment of organ system functions, including renal, hepatic and hematopoietic function, is advisable during prolonged therapy.

A high percentage of patients with mononucleosis who receive ampicillin develop an erythematous skin rash. Thus, ampicillin class antibiotics should not be administered to patients with mononucleosis.

The possibility of superinfections with mycotic or bacterial pathogens should be kept in mind during therapy. If superinfections occur (usually involving *Pseudomonas* or *Candida*), the drug should be discontinued and/or appropriate therapy instituted.

Effects on ability to drive and use machines – None

known.

Usage in pregnancy and lactation

There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Ampicillin class antibiotics are excreted in the milk; therefore, caution should be exercised when amoxicillin and potassium clavulanate combination is administered to a nursing woman.

Usage in paediatrics

Efficacy and safety of amoxicillin and potassium clavulanate combination has been established even in neonates in suspension formulation. Paediatric patients weighing 40 kg or more should be dosed according to the adult recommendations (See DOSAGE AND ADMINISTRATION).

Usage in geriatrics

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Drug interactions

Probenecid decreases the renal tubular secretion of amoxicillin. Concurrent use with amoxicillin and potassium clavulanate combination may result in increased and prolonged blood levels of amoxicillin. Co-administration of probenecid cannot be recommended.

The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone. It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients. There are no data with amoxicillin and potassium clavulanate combination and allopurinol administered concurrently.

In common with other broad-spectrum antibiotics, amoxicillin and potassium clavulanate combination may reduce the efficacy of oral contraceptives.

Amoxicillin and potassium clavulanate combination should not be used in patients receiving disulfiram.

Prolongation of bleeding time and prothrombin time have been reported in some patients receiving the amoxicillin and potassium clavulanate combination.

Hence the drug should be used with care in patients on anticoagulation therapy.

ADVERSE REACTIONS

Amoxicillin and potassium clavulanate combination is generally well tolerated. The most frequently reported adverse effects were diarrhea/loose stools, nausea, skin rashes and urticaria, vomiting and vaginitis. The overall incidence of side effects, and in particular diarrhea, increased with the higher recommended dose. Other less frequently reported reactions include:

abdominal discomfort, flatulence and headache.

The following adverse reactions have been reported for ampicillin class antibiotics:

Gastrointestinal: Diarrhea, nausea, vomiting, indigestion, gastritis, stomatitis, glossitis, black "hairy" tongue, mucocutaneous candidiasis, enterocolitis, and hemorrhagic / pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment.

Hypersensitivity Reactions: Skin rashes, pruritus, urticaria, angioedema, serum sickness-like reactions (urticaria or skin rash accompanied by arthritis, arthralgia, myalgia and frequently fever), erythema multiforme (rarely Stevens-Johnson Syndrome), acute generalized exanthemous pustulosis and an occasional case of exfoliative dermatitis (including toxic epidermal necrolysis) have been reported. These reactions may be controlled with antihistamines and, if necessary, systemic corticosteroids. Whenever such reactions occur, the drug should be discontinued, unless the opinion of the physician dictates otherwise. Serious and occasional fatal hypersensitivity (anaphylactic) reactions can occur with oral penicillin.

Liver: A moderate rise in AST (SGOT) and/or ALT (SGPT) has been noted in patients treated with ampicillin class antibiotics but the significance of these findings is unknown. Hepatic dysfunction, including increases in serum transaminases (AST and/or ALT), serum bilirubin and/or alkaline phosphatase, has been infrequently reported with amoxicillin and potassium clavulanate combination. It has been reported more commonly in the elderly, in males, or in patients on prolonged treatment. The histologic findings on liver biopsy have consisted of predominantly cholestatic, hepatocellular, or mixed cholestatic-hepatocellular changes. The onset of signs/symptoms of hepatic dysfunction may occur during or several weeks after therapy has been discontinued. The hepatic dysfunction, which may be severe, is usually reversible. On rare occasions, deaths have been reported. These have generally been cases associated with serious underlying diseases or concomitant medications.

Renal: Interstitial nephritis and hematuria have been reported rarely.

Hemic and Lymphatic Systems: Anemia, including hemolytic anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia and agranulocytosis have been reported during therapy with penicillins. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena. A slight thrombocytosis was noted in less than 1% of the patients treated with amoxicillin and potassium clavulanate combination. There have been reports of increased prothrombin time in patients receiving amoxicillin and potassium clavulanate combination and anticoagulant therapy concomitantly.

Central Nervous System: Agitation, anxiety, behavioral changes, confusion, convulsions,

dizziness, insomnia, and reversible hyperactivity have been reported rarely.

Miscellaneous: Tooth discoloration (brown, yellow or gray staining) has been rarely reported. Most reports occurred in paediatric patients. Discoloration was reduced or eliminated with brushing or dental cleaning in most cases.

OVERDOSAGE

Following overdosage, patients have experienced primarily gastrointestinal symptoms including stomach and abdominal pain, vomiting, and diarrhea. Rash, hyperactivity, or drowsiness have also been observed in a small number of patients.

Interstitial nephritis resulting in oliguric renal failure has been reported in a small number of patients after overdosage with amoxicillin.

Crystalluria, in some cases leading to renal failure, has also been reported after amoxicillin overdosage in adult and pediatric patients. In case of overdosage, adequate fluid intake and diuresis should be maintained to reduce the risk of amoxicillin crystalluria. Renal impairment appears to be reversible with cessation of drug administration. High blood levels may occur more readily in patients with impaired renal function because of decreased renal clearance of both amoxicillin and clavulanate.

In the case of overdosage, discontinue the drug, treat symptomatically, and institute supportive measures as required. If the overdosage is very recent and there is no contraindication, an attempt at emesis or other means of removal of drug from the stomach may be performed. A prospective study of 51 paediatric patients at a poison center suggested that overdoses of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms and do not require gastric emptying. Both amoxicillin and clavulanate are removed from the circulation by hemodialysis.

DOSAGE AND ADMINISTRATION

Amoxicillin and potassium clavulanate combination may be taken without regard to meals; however, absorption of potassium clavulanate is enhanced when amoxicillin and potassium clavulanate combination is administered at the start of a meal. To minimize the potential for gastrointestinal intolerance, the drug should be taken at the start of a meal. Duration of therapy should be appropriate to the indication and should not exceed 14 days without review.

Adults: The usual adult dose is one Clavospey-625 tablet every 12 hours or one Clavospey-375 tablet every 8 hours. For more severe infections and infections of the respiratory tract, the dose should be one Clavospey- 1g tablet every 12 hours or one Clavospey-625 tablet every 8 hours.

Paediatric Patients: Clavospey-375, Clavospey-625 and Clavospey-1g tablet is suitable for paediatric patients weighing 40 Kgs or more. Paediatric patients weighing 40 kg or more should be dosed according to

the adult recommendations.

Usage in renal impairment: Patients with impaired renal function do not generally require a reduction in dose unless the impairment is severe. Severely impaired patients with a glomerular filtration rate of <30 mL/min. should not receive Clavospey-1g tablet. Patients with a glomerular filtration rate of 10 to 30 ml/minute should receive Clavospey-625 or Clavospey-375 tablet every 12 hours, depending on the severity of the infection. Patients with a less than 10 ml/minute glomerular filtration rate should receive Clavospey-625 or Clavospey-375 tablet every 24 hours, depending on severity of the infection. Hemodialysis patients should receive Clavospey-625 or Clavospey-375 tablet every 24 hours, depending on severity of the infection. They should receive an additional dose both during and at the end of dialysis. **Usage in hepatic impairment:** Hepatically impaired patients should be dosed with caution and hepatic function monitored at regular intervals.

CAUTION

Foods, Drugs, Devices and Cosmetics Act prohibits dispensing without prescription.

STORAGE

Store at temperatures not exceeding 30°C
KEEP OUT OF REACH OF CHILDREN.

AVAILABILITY

Co-amoxiclav
500 mg/125 mg Film-Coated Tablet
Clavospey
In box of 21's (Foil strip of 3 tablets)

Co-amoxiclav
875 mg/125 mg Film-Coated Tablet
Clavospey
In Box of 14's (Foil Strip of 2 tablets) &
In Box of 21's (Foil Strip of 3 tablets)

For suspected adverse drug reaction, report to FDA at www.fda.gov.ph

Imported & Distributed by
Blue Global (FZE)
Unit 1014, Cityland Condominium 10 Tower 2,
H.V. Dela Costa Street, Makati City, Philippines

Distributed by:
SPEY PHILIPPINES INC.
Unit 2305 Medical Plaza Ortigas,
No. 25 San Miguel Avenue,
Brgy. San Antonio, Ortigas Center
Pasig City, Philippines

Manufactured by
Ipca Laboratories Ltd.
Plot No. 69-72 (B), Sector II, KSEZ,
Gandhidham 370 230, India